Mexicor, 50 mg/ml 2 ml 10 pcs

Mexicor® reduces manifestations of oxidative stress by inhibiting free-radical lipid peroxidation and increasing the activity of antioxidant enzyme system. It improves cellular energy exchange by activating the energy-synthesizing functions of mitochondria, increasing compensatory activation of aerobic glycolysis, and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with increased delivery and consumption of succinate by cells, realization of the phenomenon of rapid oxidation of succinate acid by succinate dehydrogenase, as well as with activation of the mitochondrial respiratory chain. Upon dissociation of Mexicor® in the cell into succinate and 3-oxypyridine derivative (base), the base exhibits antioxidant effect that stabilizes cell membranes and restores functional activity of cells.

The action of the drug is based on its antioxidant activity, the ability to inhibit free-radical processes (whose pronounced intensification is observed during ischemia and myocardial necrosis, especially during reperfusion) and reduces the damaging effects of free radicals on cardiomyocytes.

It decreases cell membrane viscosity and increases its fluidity and modulates membrane-bound enzymes (calcium-independent FDE, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which help to maintain the structural and functional integrity of biomembranes and improve neurotransport and synaptic transmission. It improves metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.

It improves functional state of ischemic myocardium, cardiac contractile function, and reduces manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction, which is a significant reserve for increasing the contractility of the heart in patients with CHD complicated by heart failure.

In patients with stable angina pectoris the drug increases exercise tolerance and antianginal activity of nitro medicines and improves rheological properties of blood. Adding Mexicor® to standard therapy of CHD improves clinical condition of patients, increases exercise tolerance and improves quality of life.

Mexicor® stabilizes membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculatory disorders at early stages of atherogenesis, has hypolipidemic effect, decreases total cholesterol and low-density lipoproteins (LDL).

Mexicor® causes neuroprotective action on the functional activity and metabolism of ischemic brain, increases resistance of cerebral blood circulation in hypoperfusion, prevents decrease of cerebral blood flow in reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by inhibiting the depletion of carbohydrate stores, blocking the post-ischemic fall in glucose and oxygen utilization by the brain and preventing the progressive accumulation of lactate. At the same time, indicators of autoregulatory responses of cerebral vessels are improved.

Mexicor® has nootropic properties, prevents and reduces learning and memory disorders of acute and chronic cerebral vascular diseases, mild and moderate cognitive disorders of different genesis, has an antioxidant effect, increases concentration and performance.

Inclusion of Mexicor® in treatment of patients with acute stroke reduces clinical manifestations of stroke and improves rehabilitation period.

Mexicor® has a selective, not accompanied by sedation and muscle relaxation, anxiolytic action, eliminates anxiety, fear, tension and restlessness and improves adaptation and emotional status.

Indications

coronary heart disease (as part of complex therapy);
ischemic stroke (as part of complex therapy);
dyscirculatory encephalopathy;
mild to moderate cognitive impairment.

Pharmacological effect

Mexicor® reduces the manifestations of oxidative stress by inhibiting free radical lipid peroxidation and increasing the activity of the antioxidant enzyme system. Improves cellular energy metabolism, activating the energy-synthesizing functions of mitochondria, enhancing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate by cells, the implementation of the phenomenon of rapid oxidation of succinic acid by succinate dehydrogenase, as well as with the activation of the mitochondrial respiratory chain. When the Mexicor® drug dissociates in the cell into succinate and a 3-hydroxypyridine derivative (base), the base exhibits an antioxidant effect that stabilizes cell membranes and restores the functional activity of cells.

The action of the drug is based on its antioxidant activity, the ability to inhibit free radical processes (pronounced intensification of which is observed during myocardial ischemia and necrosis, especially during the period of reperfusion) and reduces the damaging effect of free radicals on cardiomyocytes.

Reduces the viscosity of the cell membrane, increases its fluidity and has a modulating effect on membrane-bound enzymes (calcium-independent PDE, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which helps maintain the structural and functional integrity of biomembranes, improves the transport of neurotransmitters and synaptic transmission. Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.

Improves the functional state of ischemic myocardium, contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility during reversible cardiac dysfunction, which represents a significant reserve for increasing cardiac contractility in patients with coronary artery disease complicated by heart failure.

In patients with stable angina pectoris, it increases tolerance to physical activity and the antianginal activity of nitro drugs, improves the rheological properties of blood. The addition of Mexicor® to standard therapy for coronary artery disease improves the clinical condition of patients, increasing exercise tolerance and improving quality of life.

Mexicor® stabilizes the membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculation disorders in the early stages of atherogenesis, has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins (LDL).

Mexicor® has a neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases the stability of cerebral circulation in conditions of hypoperfusion, and prevents a decrease in cerebral blood flow during the reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by inhibiting the depletion of carbohydrate reserves, blocking the post-ischemic drop in the utilization of glucose and oxygen by the brain and preventing the progressive accumulation of lactate. At the same time, the indicators of autoregulatory reactions of cerebral vessels improve.

Mexicor® has nootropic properties, prevents and reduces learning and memory impairments that occur in acute and chronic vascular diseases of the brain, mild and moderate cognitive impairment of various origins, has an antioxidant effect, increases concentration and performance.

The inclusion of the drug Mexicor® in complex therapy of patients with acute cerebrovascular accident reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period.

Mexicor® has a selective anxiolytic effect, not accompanied by sedation and muscle relaxation, eliminates anxiety, fear, tension, restlessness, increases adaptation and emotional status.

Special instructions

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Active ingredient:

ethylmethylhydroxypyridine succinate 50 mg;

Excipients:

succinic acid;

disodium edetate;

water for injections;

Contraindications

hypersensitivity to the drug;
acute dysfunction of the liver and kidneys;
pregnancy;
breastfeeding period;
age under 18 years (efficacy and safety have not been established).

Overdose

Symptoms: sleep disturbance (insomnia), in rare cases – a slight and short-term (up to 1.5–2 hours) increase in blood pressure.

Treatment: the development of overdose symptoms, as a rule, does not require the use of relief drugs; these symptoms of sleep disturbance disappear on their own within 24 hours.

In especially severe cases, it is recommended to use one of the hypnotics and anxiolytics for oral administration (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg). If blood pressure increases excessively, prescribe antihypertensive drugs (under blood pressure control).

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

Firm Enzyme LLC, Russia